• EZ Cap EGFP mRNA: A Reporter for Delivery Design

  2026-08-28

  EZ Cap EGFP mRNA 5-moUTP is more than a fluorescence reagent: it can help deconvolute uptake, translation, and carrier performance. This guide connects Cap1 and 5-moUTP chemistry with practical decisions for mRNA delivery and macrophage-targeting studies.

• CX-5461 Workflow for RNA Polymerase I Research

  2026-08-27

  CX-5461 is an RNA polymerase I inhibitor for connecting ribosome biogenesis stress with DNA damage, mitotic catastrophe, autophagy, and senescence. This workflow translates cervical cancer findings into practical concentration design, orthogonal readouts, and cisplatin-combination experiments for cancer research.

• Catalpol for Stroke Translation: From Pathway to Proof

  2026-08-27

  Catalpol, also known as Catalpinoside, offers a mechanistically coherent framework for ischemic stroke research by linking neurogenesis, angiogenesis, and SDF-1α/CXCR4 signaling. This thought-leadership analysis translates the evidence into practical model design, product selection, and translational decision criteria.

• Baricitinib and the IL-6 Signaling Frontier

  2026-08-26

  Spatial proteomics is reframing inflammatory disease as a problem of localized cell-cell signaling. This thought-leadership guide explains how Baricitinib (LY3009104) can translate human PSC observations into mechanistic experiments while preserving selectivity, assay discipline, and translational realism.

• Palonosetron in CINV and RINV: Evidence Update

  2026-08-26

  Fabi and Malaguti’s 2013 review positioned palonosetron hydrochloride as a long-acting 5-HT3 receptor antagonist with particular value for delayed chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy. Its main contribution was to integrate receptor pharmacology, clinical trial evidence, combination therapy, and guideline recommendations while identifying unresolved questions in radiotherapy, multiple-day treatment, and breakthrough emesis.

• Chloroquine BA1002: Practical Research Workflow

  2026-08-25

  Chloroquine BA1002 provides a controlled way to perturb lysosomal pH and investigate autophagy-related, immune, anticancer, antiviral, malaria, and rheumatoid arthritis research questions. In the absence of directly matched paper evidence, use the dossier values for assay planning only and do not infer clinical efficacy, pathway selectivity, or performance in an unvalidated model.

• Hyaluronic Acid Sodium Salt for siRNA Assays

  2026-08-25

  Hyaluronic acid sodium salt supports extracellular matrix modeling, cell-migration studies, and HA-coated nanoparticle workflows. This practical guide connects Sodium hyaluronate handling with the preclinical TDRD9-siRNA lung-injury study while separating validated findings from assay-development recommendations.

• LIRP Enables Light-Controlled Gene Therapy

  2026-08-24

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates therapeutic gene expression at the translation stage, allowing transgenes to remain suppressed in darkness and become active under blue or ambient light. In mouse models of metabolic disease and retinal neovascularization, this compact switch supported reversible, tissue-compatible control of gene therapy and offered a potential safety mechanism for interrupting treatment when needed.

• Cy5 hydrazide for Nanoparticle Carbonyl Analysis

  2026-08-24

  Cy5 hydrazide converts accessible aldehyde and ketone groups into a far-red fluorescence readout for protein carbonylation, oxidized glycoproteins, oligonucleotides, and nanoparticle-associated biomolecules. This workflow pairs covalent carbonyl detection with FAST nanoparticle characterization while addressing the dye’s low aqueous solubility through controlled DMSO handling and rigorous cleanup.

• 15-PGDH Inhibition Supports Muscle Repair During Weight Loss

  2026-08-23

  A 2026 PNAS study identifies 15-PGDH inhibition as a strategy to improve skeletal muscle regeneration and force recovery during semaglutide-associated weight loss in obese mice. The work connects prostaglandin metabolism with muscle stem cell activity and regenerated myofiber growth, while showing that combined treatment can preserve the weight-loss effect of semaglutide.

• EdU Imaging Kits (Cy3) for Osteosarcoma

  2026-08-22

  EdU Imaging Kits (Cy3) convert S-phase DNA synthesis into a bright, denaturation-free Cy3 signal for microscopy and flow cytometry. This practical workflow shows how to quantify proliferation and treatment response in cisplatin-sensitive and resistant osteosarcoma models while avoiding common fixation, background, and interpretation errors.

• FOXM1–ERα Networks in Female Lung Adenocarcinoma

  2026-08-22

  The reference study integrates public transcriptomic data with ceRNA modeling and cellular experiments to investigate FOXM1 in female lung adenocarcinoma. Its central contribution is a candidate DGCR5–hsa-miR-204-5p–FOXM1–ESR1/ERα regulatory network, alongside evidence that FOXM1 influences tumor-cell growth, apoptosis, receptor interactions, and modeled immunotherapy sensitivity.

• EdU Imaging Kits (Cy3) for S-Phase Assays

  2026-08-21

  EdU Imaging Kits (Cy3) provide antibody-free fluorescent detection of DNA synthesis during S phase. The 5-ethynyl-2'-deoxyuridine imaging kit uses CuAAC click chemistry with Cy3 azide for microscopy and flow cytometry, while avoiding DNA denaturation required by many BrdU workflows.

• miR-24-3p, Sp1/PI3K, and Doxorubicin Heart Failure

  2026-08-20

  The reference study identifies miR-24-3p as a pathogenic regulator of doxorubicin-induced heart failure, linking its direct suppression of Sp1 to reduced PI3K signaling, oxidative stress, and cardiomyocyte apoptosis. By combining rat and H9c2 models with pathway inhibitors, genetic manipulation, and dual-luciferase validation, the work provides a useful mechanistic framework for studying myocardial injury while highlighting important limits for therapeutic interpretation.

• CCT007093 Workflow for PPM1D Pathway Studies

  2026-08-20

  CCT007093 is a DMSO-soluble PPM1D inhibitor for connecting phosphatase activity with P38 kinase activation, pyroptosis, and cancer-cell responses. This guide translates its biochemical and cellular profile into practical workflows for breast cancer and kidney-injury models, with controls and troubleshooting steps that help distinguish pathway engagement from nonspecific toxicity.

8647 records 9/577 page Previous Next First page 上5页 678910 下5页 Last page